Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Department of Intensive Care Medicine and Anesthesiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
J Clin Anesth. 2024 Aug;95:111418. doi: 10.1016/j.jclinane.2024.111418. Epub 2024 Mar 1.
Postoperative sore throat (POST) and hoarseness are common complications of tracheal intubation. This study aims to evaluate the efficacy of flurbiprofen administered through the subglottic port of tracheal tubes to prevent POST after cardiac surgery.
Single-center, prospective, randomized, double-blind, placebo-controlled trial.
Tertiary Care Referral University Hospital (Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome).
Included 71 patients undergoing for elective cardiac surgery. Inclusion criteria were (a) age between 50 and 75 years, (b) NYHA class I or II, (c) surgery for myocardial revascularization or valve repair or replacement under cardiopulmonary bypass.
Patients were double blind randomized to receive flurbiprofen or saline in the subglottic port of the endotracheal tube (groups F and P). The solution was injected ten minutes after tracheal tube placement, ten minutes after ICU admission and ten minutes before tracheal tube removal.
The primary outcome was to assess the effect of topical flurbiprofen administered through the subglottic port of the tracheal tube to prevent post-operative sore throat (POST). The secondary outcomes were the presence of hoarseness safety and patient's subjective satisfaction with their recovery. We did not report any exploratory outcomes.
We analyzed 68 patients, 34 patients in each group. In group F, two patients complained of POST and hoarseness (5.9%), while all controls did. The two groups significantly differed in the severity scores (VAS and TPS for sore throat and HOAR for hoarseness) at all time points. In group P, patients reported mild to moderate symptoms that significantly improved or disappeared 36 h after tracheal tube removal. According to the multivariable model, hoarseness affected women less than men, in the control group (p = 0.002). None of the patients in either group reported any adverse effects.
Repeated administration of flurbiprofen through the subglottic port of tracheal tubes reduced the incidence of sore throat and hoarseness after cardiac surgery without evidence of complications.
术后咽喉痛(POST)和声音嘶哑是气管插管的常见并发症。本研究旨在评估通过气管导管声门下部位给予氟比洛芬酯预防心脏手术后 POST 的效果。
单中心、前瞻性、随机、双盲、安慰剂对照试验。
三级转诊大学医院(罗马的 Fondazione Policlinico Universitario A. Gemelli IRCCS)。
纳入 71 例行择期心脏手术的患者。纳入标准为:(a)年龄 50-75 岁,(b)NYHA 分级 I 或 II 级,(c)体外循环下心肌血运重建或瓣膜修复或置换手术。
患者双盲随机接受气管内导管声门下部位给予氟比洛芬酯或生理盐水(F 组和 P 组)。在气管导管放置后 10 分钟、入住 ICU 后 10 分钟和气管导管拔除前 10 分钟给予溶液。
主要结局是评估通过气管导管声门下部位给予局部氟比洛芬酯预防术后咽喉痛(POST)的效果。次要结局是声音嘶哑的发生、安全性以及患者对恢复的主观满意度。我们未报告任何探索性结局。
我们分析了 68 例患者,每组 34 例。F 组有 2 例患者(5.9%)诉 POST 和声音嘶哑,而所有对照组患者均诉 POST 和声音嘶哑。两组在所有时间点的咽喉痛严重程度评分(VAS 和 TPS)和声音嘶哑严重程度评分(HOAR)方面均存在显著差异。P 组患者报告有轻度至中度症状,这些症状在气管导管拔除后 36 小时明显改善或消失。根据多变量模型,女性比男性在对照组中较少发生声音嘶哑(p=0.002)。两组均无患者报告任何不良反应。
通过气管导管声门下部位重复给予氟比洛芬酯可降低心脏手术后咽喉痛和声音嘶哑的发生率,且无并发症证据。